Wegovy vs. Zepbound when both cost $50
Short answer: Under the Bridge, price is a tie — both are $50/month — so the choice is purely clinical. The short version: Zepbound showed greater average weight loss in head-to-head trial data; Wegovy carries the cardiovascular risk-reduction indication that matters for heart-history patients; and your prescriber's judgment on your specific situation outranks both generalizations.
Program facts last verified against CMS: July 21, 2026
The honest comparison
Efficacy: in the head-to-head SURMOUNT-5 trial, tirzepatide (Zepbound) averaged roughly 20% body-weight loss versus about 14% for semaglutide (Wegovy) — a real difference on averages, though individual response varies enormously and 14% is itself a strong result. Heart protection: Wegovy holds the FDA indication for reducing cardiovascular events in people with existing heart disease — directly relevant if a prior heart attack or stroke is your qualifying condition. Tolerability: broadly similar GI-effect profiles; individuals sometimes tolerate one better than the other, and switching within the program is possible.
Practical wrinkles: Zepbound under the Bridge is KwikPen-only (a pharmacy-counter trap worth knowing), and if you have moderate-to-severe sleep apnea you're routed to Part D — where Zepbound's OSA indication applies — rather than the Bridge at all.
Take the 2-minute eligibility check →
Common questions
Which one will my doctor pick?
Commonly: Wegovy when cardiovascular history dominates the picture, Zepbound when maximum weight loss is the priority — but comorbidities, drug interactions, and supply all factor in. It's genuinely case-by-case.
Can I switch if the first one disappoints?
Yes, with your prescriber and an updated authorization. Titration restarts with the new drug, so give the first choice a fair trial through its meaningful dose range.
Where does Foundayo fit in this comparison?
As the newest covered option, it has the least public track record. Your prescriber can weigh it against these two with current data — the $50 price is identical.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF